JP2020506175A - FXIa抗体のための新規で安定な製剤 - Google Patents
FXIa抗体のための新規で安定な製剤 Download PDFInfo
- Publication number
- JP2020506175A JP2020506175A JP2019538638A JP2019538638A JP2020506175A JP 2020506175 A JP2020506175 A JP 2020506175A JP 2019538638 A JP2019538638 A JP 2019538638A JP 2019538638 A JP2019538638 A JP 2019538638A JP 2020506175 A JP2020506175 A JP 2020506175A
- Authority
- JP
- Japan
- Prior art keywords
- liquid pharmaceutical
- pharmaceutical formulation
- histidine
- concentration
- glycine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title description 48
- 238000009472 formulation Methods 0.000 title description 38
- 239000007788 liquid Substances 0.000 claims abstract description 63
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 51
- 230000009424 thromboembolic effect Effects 0.000 claims abstract description 9
- 230000001732 thrombotic effect Effects 0.000 claims abstract description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 51
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 29
- 239000004471 Glycine Substances 0.000 claims description 26
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 16
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 15
- 229920000053 polysorbate 80 Polymers 0.000 claims description 15
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 14
- 239000003381 stabilizer Substances 0.000 claims description 14
- 229940068968 polysorbate 80 Drugs 0.000 claims description 13
- DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 claims description 12
- 229940074409 trehalose dihydrate Drugs 0.000 claims description 12
- 239000000080 wetting agent Substances 0.000 claims description 8
- 239000000969 carrier Substances 0.000 claims description 7
- 238000004108 freeze drying Methods 0.000 claims description 7
- 239000003755 preservative agent Substances 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 239000003906 humectant Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims 2
- 239000012669 liquid formulation Substances 0.000 abstract description 7
- 239000004480 active ingredient Substances 0.000 abstract description 5
- 239000003114 blood coagulation factor Substances 0.000 abstract description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 abstract description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 40
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 28
- 229960002885 histidine Drugs 0.000 description 27
- 208000035475 disorder Diseases 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 21
- 201000010099 disease Diseases 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 238000002296 dynamic light scattering Methods 0.000 description 14
- 208000002815 pulmonary hypertension Diseases 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 239000000178 monomer Substances 0.000 description 11
- 238000001542 size-exclusion chromatography Methods 0.000 description 11
- 238000011084 recovery Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000007853 buffer solution Substances 0.000 description 9
- 230000015271 coagulation Effects 0.000 description 9
- 238000005345 coagulation Methods 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 7
- 208000001435 Thromboembolism Diseases 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 230000035882 stress Effects 0.000 description 7
- 208000007536 Thrombosis Diseases 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 239000012905 visible particle Substances 0.000 description 6
- 230000000007 visual effect Effects 0.000 description 6
- 208000005189 Embolism Diseases 0.000 description 5
- 108010080805 Factor XIa Proteins 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 208000019693 Lung disease Diseases 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 230000023555 blood coagulation Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000009878 intermolecular interaction Effects 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 230000000087 stabilizing effect Effects 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 238000011477 surgical intervention Methods 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 3
- 206010053159 Organ failure Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000008816 organ damage Effects 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 208000026151 Chronic thromboembolic pulmonary hypertension Diseases 0.000 description 2
- 108010062466 Enzyme Precursors Proteins 0.000 description 2
- 102000010911 Enzyme Precursors Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108010048049 Factor IXa Proteins 0.000 description 2
- 108010014173 Factor X Proteins 0.000 description 2
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 208000021124 Heritable pulmonary arterial hypertension Diseases 0.000 description 2
- 208000020875 Idiopathic pulmonary arterial hypertension Diseases 0.000 description 2
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 2
- 208000034486 Multi-organ failure Diseases 0.000 description 2
- 208000010718 Multiple Organ Failure Diseases 0.000 description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 206010069351 acute lung injury Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 210000003709 heart valve Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000001147 pulmonary artery Anatomy 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 230000008728 vascular permeability Effects 0.000 description 2
- WASZXVMLVDQNDE-UHFFFAOYSA-N 3-[(3-aminopropyl)amino]-4-hydroxybenzoic acid Chemical compound NCCCNC=1C=C(C(=O)O)C=CC=1O WASZXVMLVDQNDE-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 206010003226 Arteriovenous fistula Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000015121 Cardiac valve disease Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010014498 Embolic stroke Diseases 0.000 description 1
- 206010014522 Embolism venous Diseases 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010061932 Factor VIIIa Proteins 0.000 description 1
- 108010074864 Factor XI Proteins 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001062768 Homo sapiens Coagulation factor XI Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021133 Hypoventilation Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 description 1
- 206010024119 Left ventricular failure Diseases 0.000 description 1
- 206010025219 Lymphangioma Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027527 Microangiopathic haemolytic anaemia Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010043647 Thrombotic Stroke Diseases 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000030451 Vascular dementia disease Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 108010067369 acetylpolyamine amidohydrolase Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000012443 analytical study Methods 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- -1 aromatic alcohols Chemical class 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 208000015669 capillary disease Diseases 0.000 description 1
- 238000001818 capillary gel electrophoresis Methods 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001269 cardiogenic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229940012426 factor x Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 101150089730 gly-10 gene Proteins 0.000 description 1
- 208000007345 glycogen storage disease Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 208000034737 hemoglobinopathy Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 208000018337 inherited hemoglobinopathy Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000004115 mitral valve Anatomy 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000013483 non-reduced CGE Methods 0.000 description 1
- 150000002840 non-reducing disaccharides Chemical class 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 201000008312 primary pulmonary hypertension Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000002796 renal vein Anatomy 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 238000010911 splenectomy Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000001370 static light scattering Methods 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000009662 stress testing Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 208000004043 venous thromboembolism Diseases 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
5〜50mg/ml、好ましくは10〜40mg/mlの濃度の抗FXIa抗体BAY1213790と、
5〜30mMのヒスチジンおよび100〜200mMのグリシン、好ましくは5〜10mMのヒスチジンおよび130〜200mMのグリシンと
を含み、
pH5.5〜6.5、好ましくは5.7〜6.3を有する液体医薬製剤である。製剤は、場合により湿潤剤、保存剤、担体および安定剤からなる群から選択されるさらなる成分を含む。
5〜50mg/ml、好ましくは10〜40mg/mlの濃度の抗FXIa抗体BAY1213790と、
5〜30mMのヒスチジンおよび100〜200mMのグリシン、好ましくは5〜10mMのヒスチジンおよび130〜200mMのグリシンと、
1〜10%(w/v)の安定剤、好ましくは3〜7%(w/v)のトレハロース二水和物
を含み、
pH5.5〜6.5、好ましくは5.7〜6.3を有する液体医薬製剤である。製剤は、場合により湿潤剤、保存剤、担体および安定剤からなる群から選択されるさらなる成分を含む。
10〜40mg/mlの濃度の抗FXIa抗体BAY1213790と、
5〜10mMのヒスチジンおよび130〜200mMのグリシンと、
3〜7%(w/v)のトレハロース二水和物と、
0.005%〜0.1%(w/v)の濃度のポリソルベート80と
を含み、
pH5.7〜6.3を有する液体医薬製剤である。製剤は、場合により保存剤、担体および安定剤からなる群から選択されるさらなる成分を含む。
25mg/mlの濃度の抗FXIa抗体BAY1213790と、
10mMのヒスチジンおよび130mMのグリシンと、
5%(w/v)のトレハロース二水和物と、
0.05%(w/v)の濃度のポリソルベート80と
を含み、
pH6を有する液体医薬製剤である。製剤は、場合により保存剤、担体および安定剤からなる群から選択されるさらなる成分を含む。
分析方法の説明
タンパク質濃度(UV/VIS分光法):
タンパク質濃度は280nmでの吸収によって決定する。 起こり得る光散乱のために、試験はまた320nmで補正する。
製剤緩衝液試験は以下の原理に従う:
抗体の熱安定性(アンフォールディング)は、DSC法(DSC:示差走査熱量測定)による温度プロファイル(T:15〜105℃)によって決定する。いわゆる熱アンフォールディング(TM1)は、種々の緩衝系を比較するための尺度である:TM1値が増加するにつれて、タンパク質の熱安定性は増加する。そのため、「より高い」TM1は、関連する緩衝系における抗体の良好な安定性の指標である。
試料を、目に見える粒子の存在およびそれらの外観(フレーク/繊維)について、被保護人員によって視覚的に評価する(目視チェック)。 溶液は可能な限り目に見える粒子を含まないようにすべきである。
Akta(クロマトグラフィー)上で再緩衝する間、抗体はプロセス中に種々の表面に蓄積することができるので、回収率を決定することが可能である。したがって、プロセス中/プロセス完了後の高い回収率は、成功した最終製品のための重要な前提条件である。
測定は常に同じ温度(20〜25℃)で行われる。装置を毎日2つの標準溶液で較正し、その後、0.05pH単位を超えて逸脱してはならない対照を測定する。
SEC(サイズ排除クロマトグラフィー)は、その空間サイズに基づいてモノマーをフラグメント(低分子量LMW)およびオリゴマー(高分子量HMW)から分離する。ここでは、モノマー割合が可能な限り高くあるべきである。
医薬抗体溶液のさらなる品質基準を、動的光散乱(DLS)によって決定することができる。ここでは、分子の光散乱がその流体力学的半径を決定するために使用される。抗体の流体力学的半径は、とりわけそのコンフォメーションに依存する。ストレス試験中に、抗体のコンフォメーションはアンフォールディングまたは自己会合のために変化する可能性があり、変化はDLSによって検出可能である。
1)溶液中の抗体の濃度が増加するにつれて、分子間相互作用が増加する。力がここで引力性効果を有する場合、抗体はいわゆるオリゴマー形成する傾向がある、すなわち、以前に存在していた個々のモノマーがここでいくつかの抗体の実体を形成する。抗体実体は「より大きく」見えるので、測定された流体力学的半径は増加する。
2)周囲の媒体が抗体に対して有利/不利な電荷を有する可能性がある;この場合、それは個々のモノマーを変性(アンフォールディング)させることがある;したがって、測定された流体力学的半径も同様に「拡大」して見えるだろう。
第二ビリアル係数(A2値)の測定では、分子量の発達を静的光散乱によって記録する。この場合、動的光散乱の測定と同様に、分子間相互作用を監視することができる。分子量が濃度の増加と共に超比例的に増加する場合、抗体は凝集する傾向がある−製剤中の主な条件は「引力性」と呼ばれる。対照的に、分子量が逆比例的(sub−proportionately)に発達する場合、「反発」条件がその系で優勢である。凝集する傾向は限られている。
キャピラリー電気泳動は、その電荷により電場中で分子を分離するための分析方法である。分子の形状およびサイズもまた、ゲル様媒体による分離において役割を果たすので、ここでもまた、サイズ排除クロマトグラフィーと同様に、抗体およびその断片または凝集体が分離される。
溶液の曇りは濁度測定を用いて行う。 この場合、規定された光度の光を溶液に通過させ、次いで、どれほどのエネルギーが溶液の反対側に取り込まれるかを検出し記録することができる。曇りが増加すると、濁度も同様に増加し、溶液によってより多くの光が留置される。
BAY 1213790(抗hFXIaモノクローナル抗体)についての生化学的試験により、活性化ヒト凝固因子XI(hFXIa)に対する抗体の阻害活性が決定される。この場合、BAY1213790によるヒトFXIaの機能的中和を、蛍光発生酵素活性アッセイを使用して決定する。試験試料のEC 50値をBAY 1213790参照標準と比較する。この標準は、同等の製造方法によって製造されており、pH6、−60℃未満で10mMヒスチジン/130mMグリシン緩衝液中に保存されている。
BAY 1213790試験試料およびBAY 1213790参照標準とヒト第XIa因子(FXIa)抗原の結合を、表面プラズモン共鳴分光法(SPR、Biacore)によって決定する。試験試料の結合親和性をBAY 1213790参照標準と比較する。この標準は、同等の製造方法によって製造されており、pH6、−60℃未満で10mMヒスチジン/130mMグリシン緩衝液中に保存されている。
緩衝液スクリーニングのために、非経口剤形に適している緩衝系のpH範囲を、5.0〜7.5のpH範囲で選択した。第1の試験(熱安定性測定)で調製した製剤の抗体濃度は、約1mg/mlである。それ以上の助剤は添加しなかった。
1)視覚像
2)タンパク質回収率(C280):
3)SEC(HMW、モノマー、LMW)
4)DLS(中央値)
1.攪拌ストレス試験(300rpmおよびRTで24時間)
2.FTC−80℃(−80℃での凍結融解サイクル):
室温(>2時間)で3回の凍結および融解(>2時間)
3.FTC−20℃(−20℃での凍結融解サイクル):
室温(>2時間)で3回の凍結および融解(>2時間)
製剤の粘度は濃度に依存し、タンパク質濃度に応じて1.14mPa*s(10mg/mL BAY 1213790)〜2.25mPa*s(40mg/mL BAY 1213790)である。試験のためにタンパク質濃度のみを変え、製剤の他の成分は変えなかった(pH6の10/130mMヒスチジン/グリシン、5%(w/v)トレハロース二水和物および0.05%(w/v)ポリソルベート80)。
25mg/mLのBAY 1213790を、5%(w/v)のトレハロース二水和物および0.05%(w/v)のポリソルベート80と共に、pH6の10mMヒスチジン/130mMグリシン緩衝液(10/130 His/Gly)中に製剤化した。その後、表9に記載される凍結乾燥サイクルで製剤を凍結乾燥した。
本結果により、十分な緩衝能力を有し、ストレス試験中に最適な安定化効果を示した、pH6.0の10mMヒスチジン/130mMグリシン緩衝系を選択した。
タンパク質コンフォメーション(DLS)
分子間相互作用(A2値)
モノマー割合(SEC)
目に見える粒子(視覚像)
Claims (14)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17152108 | 2017-01-19 | ||
EP17152108.1 | 2017-01-19 | ||
PCT/EP2018/050951 WO2018134184A1 (en) | 2017-01-19 | 2018-01-16 | Novel stable formulation for fxia antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020506175A true JP2020506175A (ja) | 2020-02-27 |
JP7072577B2 JP7072577B2 (ja) | 2022-05-20 |
Family
ID=57914707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019538638A Active JP7072577B2 (ja) | 2017-01-19 | 2018-01-16 | FXIa抗体のための新規で安定な製剤 |
Country Status (25)
Country | Link |
---|---|
US (1) | US20190367636A1 (ja) |
EP (1) | EP3570882B1 (ja) |
JP (1) | JP7072577B2 (ja) |
KR (1) | KR20190105588A (ja) |
CN (1) | CN110234353B (ja) |
AR (1) | AR110762A1 (ja) |
AU (1) | AU2018209118A1 (ja) |
BR (1) | BR112019014785A2 (ja) |
CA (1) | CA3050172A1 (ja) |
CY (1) | CY1124922T1 (ja) |
DK (1) | DK3570882T3 (ja) |
ES (1) | ES2904474T3 (ja) |
HR (1) | HRP20220011T1 (ja) |
HU (1) | HUE056858T2 (ja) |
IL (1) | IL267917B2 (ja) |
LT (1) | LT3570882T (ja) |
MX (1) | MX2019008544A (ja) |
PE (1) | PE20191476A1 (ja) |
PL (1) | PL3570882T3 (ja) |
PT (1) | PT3570882T (ja) |
RS (1) | RS62780B1 (ja) |
SG (1) | SG11201906557UA (ja) |
SI (1) | SI3570882T1 (ja) |
TW (1) | TWI753087B (ja) |
WO (1) | WO2018134184A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20200312A1 (ar) | 2015-06-26 | 2017-06-16 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
TW201802121A (zh) | 2016-05-25 | 2018-01-16 | 諾華公司 | 抗因子XI/XIa抗體之逆轉結合劑及其用途 |
BR112019012667A2 (pt) | 2016-12-23 | 2020-02-11 | Novartis Ag | Anticorpos do fator xi e métodos de uso |
CR20210435A (es) | 2019-02-18 | 2021-09-20 | Lilly Co Eli | Formulación de anticuerpos terapéuticos |
KR20220119090A (ko) * | 2019-12-20 | 2022-08-26 | 안토스 테라퓨틱스, 인크. | 인자 XI/XIa 항체에 대한 제약 제제 및 투여 요법 |
WO2022002233A1 (zh) | 2020-07-03 | 2022-01-06 | 苏州康宁杰瑞生物科技有限公司 | 凝血因子xi(fxi)结合蛋白 |
WO2022122993A1 (en) * | 2020-12-11 | 2022-06-16 | Boehringer Ingelheim International Gmbh | Formulation for multi-purpose application |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040191243A1 (en) * | 2002-12-13 | 2004-09-30 | Bei Chen | System and method for stabilizing antibodies with histidine |
JP2015517305A (ja) * | 2012-05-10 | 2015-06-22 | バイエル ファーマ アクチエンゲゼルシャフト | 凝固因子xiおよび/またはその活性化形態である因子xiaに結合しうる抗体ならびにその用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002013860A1 (fr) * | 2000-08-11 | 2002-02-21 | Chugai Seiyaku Kabushiki Kaisha | Preparations stabilisees contenant un anticorps |
CA2736864C (en) * | 2008-09-19 | 2020-10-13 | Pfizer Inc. | Stable liquid antibody formulation |
CN102438652B (zh) * | 2008-11-12 | 2014-08-13 | 米迪缪尼有限公司 | 抗体制剂 |
WO2015059147A1 (en) * | 2013-10-25 | 2015-04-30 | Bayer Pharma Aktiengesellschaft | A novel stable formulation |
-
2018
- 2018-01-16 CA CA3050172A patent/CA3050172A1/en active Pending
- 2018-01-16 PT PT187026232T patent/PT3570882T/pt unknown
- 2018-01-16 WO PCT/EP2018/050951 patent/WO2018134184A1/en unknown
- 2018-01-16 RS RS20220004A patent/RS62780B1/sr unknown
- 2018-01-16 DK DK18702623.2T patent/DK3570882T3/da active
- 2018-01-16 PL PL18702623T patent/PL3570882T3/pl unknown
- 2018-01-16 JP JP2019538638A patent/JP7072577B2/ja active Active
- 2018-01-16 SI SI201830483T patent/SI3570882T1/sl unknown
- 2018-01-16 LT LTEPPCT/EP2018/050951T patent/LT3570882T/lt unknown
- 2018-01-16 AU AU2018209118A patent/AU2018209118A1/en active Pending
- 2018-01-16 IL IL267917A patent/IL267917B2/en unknown
- 2018-01-16 ES ES18702623T patent/ES2904474T3/es active Active
- 2018-01-16 HU HUE18702623A patent/HUE056858T2/hu unknown
- 2018-01-16 KR KR1020197020744A patent/KR20190105588A/ko active IP Right Grant
- 2018-01-16 MX MX2019008544A patent/MX2019008544A/es unknown
- 2018-01-16 CN CN201880007721.1A patent/CN110234353B/zh active Active
- 2018-01-16 HR HRP20220011TT patent/HRP20220011T1/hr unknown
- 2018-01-16 US US16/478,029 patent/US20190367636A1/en not_active Abandoned
- 2018-01-16 SG SG11201906557UA patent/SG11201906557UA/en unknown
- 2018-01-16 EP EP18702623.2A patent/EP3570882B1/en active Active
- 2018-01-16 BR BR112019014785-3A patent/BR112019014785A2/pt unknown
- 2018-01-16 PE PE2019001433A patent/PE20191476A1/es unknown
- 2018-01-17 TW TW107101631A patent/TWI753087B/zh active
- 2018-01-19 AR ARP180100130A patent/AR110762A1/es unknown
-
2022
- 2022-01-05 CY CY20221100009T patent/CY1124922T1/el unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040191243A1 (en) * | 2002-12-13 | 2004-09-30 | Bei Chen | System and method for stabilizing antibodies with histidine |
JP2015517305A (ja) * | 2012-05-10 | 2015-06-22 | バイエル ファーマ アクチエンゲゼルシャフト | 凝固因子xiおよび/またはその活性化形態である因子xiaに結合しうる抗体ならびにその用途 |
Non-Patent Citations (1)
Title |
---|
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 78, JPN6021045043, 2011, pages 208 - 212, ISSN: 0004638422 * |
Also Published As
Publication number | Publication date |
---|---|
SI3570882T1 (sl) | 2022-01-31 |
EP3570882B1 (en) | 2021-11-17 |
HUE056858T2 (hu) | 2022-03-28 |
CN110234353B (zh) | 2023-07-04 |
CY1124922T1 (el) | 2023-01-05 |
HRP20220011T1 (hr) | 2022-04-01 |
PT3570882T (pt) | 2022-01-11 |
DK3570882T3 (da) | 2022-01-10 |
IL267917B2 (en) | 2023-10-01 |
IL267917B1 (en) | 2023-06-01 |
RU2019125947A3 (ja) | 2021-05-25 |
EP3570882A1 (en) | 2019-11-27 |
WO2018134184A1 (en) | 2018-07-26 |
CA3050172A1 (en) | 2018-07-26 |
PL3570882T3 (pl) | 2022-02-07 |
TWI753087B (zh) | 2022-01-21 |
ES2904474T3 (es) | 2022-04-05 |
CN110234353A (zh) | 2019-09-13 |
IL267917A (en) | 2019-09-26 |
RS62780B1 (sr) | 2022-01-31 |
PE20191476A1 (es) | 2019-10-16 |
US20190367636A1 (en) | 2019-12-05 |
MX2019008544A (es) | 2019-10-07 |
TW201831170A (zh) | 2018-09-01 |
KR20190105588A (ko) | 2019-09-17 |
BR112019014785A2 (pt) | 2020-05-12 |
AU2018209118A1 (en) | 2019-07-11 |
LT3570882T (lt) | 2021-12-10 |
SG11201906557UA (en) | 2019-08-27 |
AR110762A1 (es) | 2019-05-02 |
JP7072577B2 (ja) | 2022-05-20 |
RU2019125947A (ru) | 2021-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7072577B2 (ja) | FXIa抗体のための新規で安定な製剤 | |
US9987328B2 (en) | Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces | |
Davies et al. | Plasma acetate, gluconate and interleukin-6 profiles during and after cardiopulmonary bypass: a comparison of Plasma-Lyte 148 with a bicarbonate-balanced solution | |
US20230346839A1 (en) | Blood plasma-containing compositions | |
Van der Linden et al. | 3.5% urea-linked gelatin is as effective as 6% HES 200/0.5 for volume management in cardiac surgery patients | |
JP2010006839A (ja) | 組織因子経路インヒビター(tfpi)の低量投与による敗血症の処置 | |
Bhole et al. | Therapeutic potential of targeting the complement cascade in critical care medicine | |
Levy et al. | Recombinant human transgenic antithrombin in cardiac surgery: a dose-finding study | |
TW202310873A (zh) | 含有抗人類tslp受體抗體之醫藥組成物 | |
JP3362038B2 (ja) | 抗凝血剤 | |
RU2775692C2 (ru) | Новые стабильные композиции для fxia антител | |
Muralidhar et al. | Influence of colloid infusion on coagulation during off-pump coronary artery bypass grafting | |
KR20210028673A (ko) | 항-FXIa 항체에 대한 신규한 안정한 고농도 제형물 | |
Ege et al. | Importance of pulmonary artery perfusion in cardiac surgery | |
JP2009539757A (ja) | 血栓溶解活性を有するadamts13含有組成物 | |
EP1948216A2 (en) | Method of treating acute failure with thrombomodulin variant | |
Shorbagy et al. | Effectiveness of minimal acute normovolemic hemodilution to minimize allogenic blood transfusion and re-exploration in elective adult coronary artery bypass graft surgery using colloid as a replacement solution. | |
Strengers et al. | Blood, blood components, plasma, and plasma products | |
Price et al. | AFFILIATIONS 16 | |
Solomon | Mechanisms of canine endotoxin shock: modification of the shock state by salicylates | |
Dolich et al. | Hypovolemic and Septic Shock | |
JPH09104637A (ja) | 過凝固または低線溶状態およびその類縁疾患の予防治療剤 | |
Wildes et al. | Essential drugs in anesthetic practice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201118 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211115 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220215 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220325 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220411 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220510 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7072577 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |